Syndax Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Syndax Pharmaceuticals, Inc. (SNDX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-318.76-209.36-149.3424.93-73.16
Depreciation & Amortization0.010.010.030.040.09
Stock Based Compensation43.0330.9516.0213.329.06
Change in Working Capital13.2731.861.66-9.60-7.93
Change in Accounts Receivable-11.240.000.000.000.00
Change in Inventory-0.370.000.000.000.00
Change in Accounts Payable1.675.61-1.322.16-2.67
Change in Other Working Capital23.2126.252.981.38-3.75
Other Operating Activities0.990.741.34-0.200.82
Net Cash from Operating Activities-274.90-160.60-133.6829.13-71.26
Investing Activities
Capital Expenditures0.000.000.00-0.130.00
Purchases of Investments-219.78117.61-186.41-40.74-142.53
Sales/Maturities of Investments337.28472.22308.93253.980.00
Net Cash from Investing Activities-219.78117.61-186.19-40.87-142.53
Financing Activities
Debt Repayment0.000.00-21.000.000.00
Common Stock Issued9.72264.13193.25117.89284.69
Other Financing Activities343.650.000.000.580.00
Net Cash from Financing Activities353.37264.13172.25118.46304.42
Summary
Net Change in Cash-141.31221.14-147.61106.7290.63
Cash at Beginning of Period295.6174.47222.08115.360.00
Cash at End of Period154.30295.6174.47222.080.00
Free Cash Flow-274.90-160.60-133.6829.00-71.26
Supplemental Disclosures
Interest Paid0.000.002.062.001.63